- In April 2025, researchers published a review in Nature Reviews Clinical Oncology highlighting the growing significance of epigenetic modifications as therapeutic targets in oncology and beyond. The study emphasized that the next generation of epigenetic drugs is focusing on precise modulation of gene expression without altering DNA sequences, holding promise for cancer, autoimmune, and neurological disorders
- In March 2025, the Keystone Symposia hosted a major conference titled "Epigenetics in Development and Disease" in Banff, Canada. The event brought together leading researchers and biotech innovators to discuss advancements in chromatin biology, histone modifications, and transcriptional regulation, underlining their implications for precision medicine and regenerative therapy
- In November 2024, Tune Therapeutics, a U.S.-based epigenetic medicine company, announced that its therapy Tune-401—targeting chronic hepatitis B virus (HBV)—is preparing for clinical trials. The therapy uses the company's proprietary "Epigenetic Reprogramming" technology to silence viral gene expression, showing promise in preclinical models as a potential cure rather than a suppression therapy
- In October 2024, Wired magazine reported on a new wave of epigenetic editing technologies, which aim to fine-tune gene expression without modifying the DNA code itself. These tools—distinct from CRISPR—are gaining traction in neuroscience, with recent animal studies demonstrating that targeted epigenetic modulation can reverse anxiety behaviors and addiction tendencies
- In December 2023, BioLabs and Promega expanded their collaborative efforts to drive global innovation in life sciences by supporting early-stage startups. Promega GmbH, the German subsidiary of the global life sciences manufacturer, located in Walldorf, now provides advanced equipment, comprehensive services, and specialized training to BioLabs Heidelberg, enhancing their capacity to nurture emerging biotech ventures
